Looks as though IMUC has the attention of the medical world with the response and attention they received at the SNO conference. Based on what I've read it seems to validate that immunotherapy treatments such as ICT-107 is showing the most promise for the future of cancer treatment. Seems as though it's only a matter of time before PFE, MRK, AZN, GSK, and the other large pharmaceutical players take notice.
"Company also presented data comparing ICT-107 vs a tumor lysate vaccine in a concurrent trial conducted with the same patient characteristics giving significant credibility to the data."
My interest, and I'm sure that of major investors, has always been tempered by the small sample size in their Phase I trial. This updated news goes some way in alleviate those reservations. Alas, there will be very few opportunities for news to drive the pps til prelim. P II results(April/May at the eariest?).